CN113493600A - Biodegradable PDT/Fe3O4Method for preparing composite material - Google Patents

Biodegradable PDT/Fe3O4Method for preparing composite material Download PDF

Info

Publication number
CN113493600A
CN113493600A CN202010270964.3A CN202010270964A CN113493600A CN 113493600 A CN113493600 A CN 113493600A CN 202010270964 A CN202010270964 A CN 202010270964A CN 113493600 A CN113493600 A CN 113493600A
Authority
CN
China
Prior art keywords
composite material
pdt
biodegradable
ferroferric oxide
oxide nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010270964.3A
Other languages
Chinese (zh)
Inventor
刘昌胜
李玉林
罗炜
刘天舒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East China University of Science and Technology
Original Assignee
East China University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by East China University of Science and Technology filed Critical East China University of Science and Technology
Priority to CN202010270964.3A priority Critical patent/CN113493600A/en
Publication of CN113493600A publication Critical patent/CN113493600A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K3/00Use of inorganic substances as compounding ingredients
    • C08K3/18Oxygen-containing compounds, e.g. metal carbonyls
    • C08K3/20Oxides; Hydroxides
    • C08K3/22Oxides; Hydroxides of metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02Inorganic materials
    • A61L31/028Other inorganic materials not covered by A61L31/022 - A61L31/026
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/042Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/06Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148Materials at least partially resorbable by the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/18Materials at least partially X-ray or laser opaque
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/64Polyesters containing both carboxylic ester groups and carbonate groups
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/78Preparation processes
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00Processes of treating or compounding macromolecular substances
    • C08J3/20Compounding polymers with additives, e.g. colouring
    • C08J3/205Compounding polymers with additives, e.g. colouring in the presence of a continuous liquid phase
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2367/00Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
    • C08J2367/04Polyesters derived from hydroxy carboxylic acids, e.g. lactones
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2369/00Characterised by the use of polycarbonates; Derivatives of polycarbonates
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K3/00Use of inorganic substances as compounding ingredients
    • C08K3/18Oxygen-containing compounds, e.g. metal carbonyls
    • C08K3/20Oxides; Hydroxides
    • C08K3/22Oxides; Hydroxides of metals
    • C08K2003/2265Oxides; Hydroxides of metals of iron
    • C08K2003/2275Ferroso-ferric oxide (Fe3O4)
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K2201/00Specific properties of additives
    • C08K2201/01Magnetic additives
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K2201/00Specific properties of additives
    • C08K2201/011Nanostructured additives
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2201/00Properties
    • C08L2201/06Biodegradable

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The invention relates to the field of medical composite materials, and discloses poly (racemic lactide-trimethylene carbonate)/nano ferroferric oxide (PDT/Fe) with biocompatibility and biodegradability3O4) A composite material, the method comprising: the synthesized PDT and a certain amount of magnetic nano Fe3O4Compounding by mechanical stirring in an organic solvent, precipitating, vacuum drying, and hot pressing with a flat vulcanizing machine to obtain a thin sheet. PDT-Fe synthesized by the invention3O4The composite material belongs to a flexible material, and has good imaging function, biological absorbability and biodegradability aiming at the outstanding problems of poor developing sensitivity, biological inertia, rejection reaction and the like of the traditional metal marking clip.

Description

Biodegradable PDT/Fe3O4Method for preparing composite material
Technical Field
The invention relates to the field of nano medical composite materials, in particular to a medical composite material with good imaging function, biological absorbability and biodegradability and a preparation method thereof.
Background
In recent years, the incidence rate of breast cancer is high, and the incidence rate of breast cancer in women is the first place of malignant tumor worldwide. Among the various neoplastic diseases, breast cancer is the first leading killer faced by women. Breast cancer-preserving breast therapy recommends postoperative radiation therapy to reduce the risk of local recurrence, wherein Whole Breast Irradiation (WBI) is the leading mode of postoperative radiation therapy, but recent research data show that, for early-stage breast cancer patients, Partial Breast Irradiation (PBI) is the same as WBI, which can reduce the local recurrence rate, and meanwhile, the adverse reaction of radiation therapy and the cosmetic effect are similar, and PBI can replace WBI to a certain extent, while the key point of realizing PBI lies in the accurate positioning of a tumor target area.
The breast cancer postoperative locating clip that currently is clinically commonly used is titanium clip or silver clip mostly, and postoperative radiotherapy indicating action effect is better, but is inert metal, settles and exists for a long time after internal, can't be corroded or degrade, causes great psychological burden for the patient easily, and some case can form local induration simultaneously, influences the differentiation of postoperative follow-up to local relapse, and most patients hold passive accepting state to the metal frame, all brings certain puzzlement for doctor and patient. Therefore, the preparation of a composite material with good developability, excellent degradability and biocompatibility for a marking clip is urgently needed in the field, and the outstanding problems of poor image sensitivity, biological inertness, biological rejection and the like of the traditional metal clip are solved.
Disclosure of Invention
The invention aims to provide a composite material with good developability, excellent degradability and biocompatibility for a marking clip, and solves the outstanding problems of poor image sensitivity, biological inertia, biological rejection and the like of the traditional metal clip.
In a first aspect of the present invention, there is provided a composite material for development, the composite material being in a solid state and comprising: (a) biodegradable and biocompatible polymers; and (b) ferroferric oxide nanoparticles for development, wherein the average particle diameter of the ferroferric oxide nanoparticles is 50-500nm, and the ferroferric oxide nanoparticles are uniformly dispersed in the biodegradable and biocompatible polymer.
In another preferred embodiment, said (a) biodegradable and biocompatible polymer is selected from the group consisting of: PDT, PGA, PLA, PCL, chitosan, hyaluronic acid, etc.
In another preferred embodiment, said (a) biodegradable and biocompatible polymer is PDT polymer.
In another preferred embodiment, said PDT polymer has a molecular weight of 100 × 103~300×103Mass-average relative molecular weight of 200X 103~500×103What is, what isThe Polymer Dispersion Index (PDI) is 1-2.5, and has the following characteristics: the molecular weight distribution is narrow, and the molding is easy.
In another preferred example, the average particle size of the ferroferric oxide nanoparticles for developing (b) is 50-500 nm.
In another preferred embodiment, the content of the ferroferric oxide nanoparticles for developing (b) is 0.1-8 wt% based on the total weight of the composite material.
In another preferred embodiment, the weight ratio of the ferroferric oxide nanoparticles to the biodegradable and biocompatible polymer is 0.25-10: 100, preferably 0.5-5: 100.
in another preferred example, the ferroferric oxide nanoparticles have superparamagnetism.
In another preferred example, the ferroferric oxide nanoparticles also have the following characteristics: the polydispersity index of the nanoparticles is 0.01-0.4.
In another preferred embodiment, the nano Fe3O4The mass concentration of the/PDT is 0.5-5%, preferably 0.5%, 1%, 2% or 4%.
In another preferred embodiment, the composite material also has the following characteristics:
(i) developing property: the CT value is obviously different from that of soft tissues;
(ii) biodegradability: can be degraded into micromolecular aliphatic hydroxy acid in biological environment;
(iii) biocompatibility: cytotoxicity is less than grade 1;
(iv) mechanical properties: the tensile modulus is 10-200MPa, the tensile strength is 5-20MPa, and the elongation at break is 400-900%.
In a second aspect of the present invention, there is provided a method for preparing the composite material of the first aspect of the present invention, comprising the steps of:
(S1) mixing the ferroferric oxide nanoparticles, the biodegradable and biocompatible polymer and the first solvent to form a first mixture, wherein the biodegradable and biocompatible polymer is soluble in the first solvent;
(S2) adding a second solvent to the first mixture, thereby forming a precipitate from the composite of the ferroferric oxide nanoparticles and the biodegradable and biocompatible polymer; and
(S3) separating the precipitate and drying to obtain the composite material of claim 1.
In another preferred embodiment, the biodegradable and biocompatible polymer is a PDT polymer.
In another preferred embodiment, the first solvent is selected from the group consisting of: dichloromethane, trichloromethane and acetone. In another preferred embodiment, the second solvent is selected from the group consisting of: absolute ethyl alcohol, deionized water and absolute ethyl ether.
In another preferred example, the step (S1) includes the steps of: dissolving the biodegradable and biocompatible polymer in a first solvent to form a first solution; and then adding the ferroferric oxide nano particles into the first solution to form a first mixture.
In another preferred embodiment, the first solution is a PDT solution comprising a biodegradable and biocompatible polymer dissolved in methylene chloride solvent at a concentration of 0.5-0.2g/mL (preferably 0.08-0.12g/mL, more preferably about 0.1 g/mL).
In another preferred example, the step (S3) includes: separating the precipitate, and carrying out vacuum drying and hot pressing to obtain a molded product.
In another preferred embodiment, the vacuum drying is carried out at 60. + -. 10 ℃ overnight.
In another preferred example, the hot pressing is hot pressing by a flat vulcanizing machine.
In another preferred embodiment, the molded product is a sheet having a thickness of about 0.2. + -. 0.05 mm.
In another preferred embodiment, said biodegradable and biocompatible polymer is a PDT polymer, and, before step (S1), further comprising a step for preparing PDT:
(S01) under the protection of inert gas, in stannous octoate Sn (Oct)2Racemizing the monomer in the presence of a catalystReacting lactide (DLLA) with trimethylene carbonate (TMC) to form a reaction product;
(S02) dissolving the reaction product in a first solvent to form a solution;
(S03) adding a second solvent to the solution in the previous step, thereby forming a precipitate;
(S04) separating the precipitate, dissolving in a first solvent to form a solution, and repeating the step (S03), wherein the step (S04) can be repeated 0-2 times; and
(S05) separating the precipitate in the previous step and drying, thereby obtaining a PDT material.
In another preferred example, in the step (S01), the reaction is carried out under the protection of argon and heating condition for a period of time TS01Thereby obtaining a reaction product.
In another preferred example, in the step (S01), the molar ratio of the monomeric racemic lactide (DLLA) to trimethylene carbonate (TMC) is 60-75: 20 to 50, preferably 70: 20 to 50.
In another preferred embodiment, the catalyst is stannous octoate Sn (Oct)2And the mass ratio of the monomer to the monomer (racemic lactide (DLLA) + trimethylene carbonate (TMC)) is 1.0-1.5: 1000.
in another preferred example, in the step (S01), the heating condition is 100 to 150 ℃; and TS01Is 1 to 24 hours, preferably 2 to 10 hours.
In another preferred example, in the step (S05), the drying is vacuum drying.
In another preferred example, the reaction product obtained in the step (S01) is subjected to purification and vacuum drying, heat-sealed with aluminum foil, and then stored at low temperature (e.g., about-20 ℃).
In another preferred example, before the step (S1), a step for preparing the ferroferric oxide nanoparticles is further included:
(F1) FeCl is added3And FeSO4Dissolving in water to obtain Fe3+/Fe2+The molar ratio is 2:1, yellow-green ferric salt solution;
(F2) dropwise adding the ferric salt solution into (F1) NaOH solution (with the concentration of 0.5-2mol/L), and violently stirring for 5-15 min under ultrasonic to form black suspension;
(F3) introducing argon gas into the black suspension, stirring, and reacting at 50-100 ℃ for 20-60 (such as about 30min) to form ferroferric oxide nanoparticles;
(F4) magnetically separating the ferroferric oxide nano particles, alternately washing with deoxygenated distilled water and absolute ethyl alcohol, and dispersing with deoxygenated distilled water;
(F5) and (3) freeze-drying the product, and then carrying out vacuum drying at 20-100 ℃ to obtain the ferroferric oxide nanoparticles.
In a third aspect of the invention there is provided an article comprising or made from a composite material according to the first aspect of the invention.
In another preferred embodiment, the product is a marking clip and has the following characteristics: the clamp body is indefinite in shape, and the tail end of the clamp body is provided with a needle hole, so that the clamp body can be fixed at a required position by a suture.
In another preferred embodiment, the article is made by the method of the second aspect of the present invention.
In a fourth aspect of the invention there is provided the use of an article according to the third aspect of the invention for the manufacture of a marker clip for post-operative localization of breast cancer or also for tracing of degradation of polymers in vivo, as a drug carrier and in magneto-caloric therapy.
In another preferred example, the marking clamp has developing performance, so that the tracking and identification of cancer cells after operation can be obviously improved;
in another preferred example, the marker clamp has biodegradability, and can degrade automatically after cancer cell identification and tracking is completed, so that the physiological and psychological burden of a patient is reduced;
in another preferred embodiment, the marker clip is biocompatible and can reduce rejection after implantation in a human body.
It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments. Not to be reiterated herein, but to the extent of space.
Drawings
FIG. 1 shows values of elastic modulus and tensile strength for PDT prepared with monomeric racemic lactide (DLLA) and trimethylene carbonate (TMC) at different mixing ratios, where "PDT _ X-Y" represents PDT prepared with X moles of DLLA and Y moles of TMC.
FIG. 2 shows elongation at break and energy at break of PDT prepared from monomeric racemic lactide (DLLA) and trimethylene carbonate (TMC) at different mixing ratios.
Fig. 3 shows elongation at break and tensile modulus of PDT prepared using ethanol or diethyl ether as the second solvent.
FIG. 4 shows a sample obtained by 3D printing using PDT material prepared in one embodiment of the invention.
Figure 5 shows the apparent morphology of the complex sample. Not mixed with Fe3O4The PDT is colorless, transparent and white and is compounded with 4 percent of Fe by mass3O4The composite PDT color was significantly darker.
FIG. 6 shows PDT/Fe at different mass concentrations3O4Complexes and complex sizes.
FIG. 7 shows PDT/Fe3O4The resilience test results for the composite (1%), wherein (a) is before stretching; (b) after deformation of 400%; (c) standing at 37 deg.C for 15s after deformation; (d) the sample was allowed to stand at 37 ℃ for 30 seconds after deformation.
Fig. 8 shows PDT degradation results. Wherein (a) is before degradation; (b) degradation is carried out for 4 weeks; the material before degradation was colorless and transparent, and after 4 weeks of degradation, it became milky white.
FIG. 9 shows scanning electron microscope morphologies of surface and cross-section of PDT before and after degradation. Before degradation, PDT has uniform and non-pattern surface and smooth section; after degradation, uniformly and densely small holes appear on the PDT surface, and irregular holes appear on the cross section.
FIG. 10 shows PDT/Fe3O4X-ray imaging function of the complex.
FIG. 11 shows PDT/Fe3O4Complex performance at CT. With magnetismSexual nano Fe3O4The mass fraction is increased, and the number of high-density points is obviously increased.
Detailed Description
The inventor of the present invention has made extensive and intensive studies and has unexpectedly found for the first time that a composite magnetic nano-Fe3O4Particles and absorbable Polymers (PDT) are used to prepare a composite material with good developability, degradability and biocompatibility.
Specifically, the method solves the outstanding problems of poor developing sensitivity, biological inertness, rejection reaction and the like of the traditional inert metal radiotherapy labeling clip, and can control the number average molecular mass and the dispersity index (PDI) of the obtained polymer and enhance the forming capability of PDT by controlling the ratio of the amounts of the racemic lactide (DLLA) and trimethylene carbonate (TMC) monomer substances.
Term(s) for
As used herein, the terms "composite of the present invention", "material of the present invention", "composite for development of the present invention", "composite of the present invention" and the like are used interchangeably to refer to the composite for development described in the first aspect of the present invention.
Composite material for development
The present invention provides a composite material suitable for development, said composite material being in the solid state and comprising: (a) biodegradable and biocompatible polymers; and (b) ferroferric oxide nanoparticles for development, wherein the average particle diameter of the ferroferric oxide nanoparticles is 50-500nm, and the ferroferric oxide nanoparticles are uniformly dispersed in the biodegradable and biocompatible polymer.
The composite material has the characteristics of excellent biocompatibility, high biodegradability, good imaging function and the like, and can be prepared into a proper shape or form for clinical development.
Preferably, the invention provides PDT/nano Fe with the thickness of 0.2mm3O4A composite sheet.
Preferably, said biodegradable and biocompatible polymers (also referred to as "organic medical composites") include, but are not limited to: PDT, PGA, PLA, PCL, chitosan, hyaluronic acid, or a combination thereof.
In the present invention, preferred PDT has the following characteristics: number average relative molecular weight 100X 103~300×103Mass-average relative molecular weight of 200X 103~500×103The Polymer Dispersion Index (PDI) is 1-2.5.
Preferably, PDT of the present invention is performed using a copolymer of racemic lactide (DLLA) and trimethylene carbonate (TMC), wherein the mixing ratio (by moles) of racemic lactide (DLLA) and trimethylene carbonate (TMC) is 78: 22 to 60: 40, preferably 75: 25 to 65: 35, more preferably about 70: 30.
note: the ratio is based on FIGS. 1 and 2 and the following table
Figure BDA0002443150690000071
Preparation method
The invention also provides a method for preparing the composite material.
Preferably, the invention provides a method for preparing PDT-nano Fe with good biological development function, biocompatibility and biodegradability3O4A preparation method of medical composite material. The method solves the outstanding problems of poor developing sensitivity, biological inertness, rejection reaction and the like of the traditional inert metal radiotherapy marking clip, and can control the number average molecular mass and the dispersion index (PDI) of the obtained polymer and enhance the forming capability of PDT by controlling the ratio of the amount of the racemic lactide (DLLA) and trimethylene carbonate (TMC) monomer substances.
Typically, the preparation method of the present invention comprises the steps of:
(S1) mixing the ferroferric oxide nanoparticles, the biodegradable and biocompatible polymer and the first solvent to form a first mixture, wherein the biodegradable and biocompatible polymer is soluble in the first solvent;
(S2) adding a second solvent to the first mixture, thereby forming a precipitate from the composite of the ferroferric oxide nanoparticles and the biodegradable and biocompatible polymer; and
(S3) separating the precipitate and drying to obtain the composite material of claim 1.
Preferably, the composite material of the invention is PDT/Fe3O4A composite material.
In a preferred embodiment, the invention provides a method of preparing PDT/Fe3O4The method for preparing the composite material specifically comprises the following steps:
(1) synthesis of PDT
S1.1, the ratio of the amounts of monomeric racemic lactide (DLLA) to trimethylene carbonate (TMC) material was 70: 10 to 50;
s1.2, selecting a catalyst stannous octoate Sn (Oct)2The mass ratio of the monomer to the monomer is 1.0 to 1.5: 1000, parts by weight;
s1.3, vacuumizing for 4 hours, heating to 100-150 ℃ in an argon atmosphere, and reacting for 2-10 hours;
s1.4, dissolving and precipitating the product for 2-3 times by using dichloromethane and absolute ethyl alcohol, purifying, and drying in vacuum at 20-100 ℃ to obtain a PDT sample.
S1.5, heat-sealing the product by using an aluminum foil, and storing the product in a refrigerator at the temperature of-20 ℃.
Typically, in the synthesis of PDT, the ratio of the amounts of racemic lactide (DLLA) and trimethylene carbonate (TMC) species is 70: 10 to 50; catalyst stannous octoate Sn (Oct)2The mass ratio of the monomer to the monomer is 1.0 to 1.5: 1000.
preferably, in the step S1.3, the temperature is raised to 100-150 ℃ in an argon atmosphere, and the reaction time is 2-10 h.
(2) Nano Fe3O4Synthesis of (2)
S2.1, dissolving 4g of NaOH solution in 100mL of deoxidized distilled water, and stirring to completely dissolve the NaOH solution to obtain 1mol/L of NaOH solution;
s2.2, respectively taking 5.40g FeCl3.6H2O and2.78gFeSO4.7H2dissolving O in 20mL of deoxidized distilled water to obtain a yellow-green iron salt solution;
s2.3, dropwise adding the solution obtained in the step S2 into the solution S1 at room temperature, and carrying out ultrasonic vigorous stirring for 5-15 min;
s2.4, mechanically stirring the black suspension obtained in the step S3, introducing argon, and reacting for 30min at 50-100 ℃;
s2.5, magnetically separating a product obtained in the step S4, alternately washing the product for 2 times by using deoxygenated distilled water and absolute ethyl alcohol, and dispersing the product by using the deoxygenated distilled water and the absolute ethyl alcohol;
s2.6, freeze-drying the product, then carrying out vacuum drying at 20-100 ℃ overnight, and putting the product into a dryer for vacuum storage.
Preferably, Fe is obtained after the iron salt in the step S2.2 is dissolved3+/Fe2+A yellow-green iron salt solution in a molar ratio of about 2: 1.
(3)PDT/Fe3O4Preparation of the Complex
S3.1, adding the PDT obtained in the step (1) into a dichloromethane solvent, and dissolving to obtain 0.1g/mL of PDT solution;
s3.2, adding a certain amount of magnetic nano Fe3O4Continuing to stir for a period of time;
s3.3, precipitating the product in the last step by using absolute ethyl alcohol, drying the product in vacuum at 60 ℃ overnight, and hot-pressing the dried product into a thin sheet with the thickness of about 0.2mm by using a flat vulcanizing machine.
Preferably, the mass ratio in step S3.2 is nano Fe3O4The mass concentration of PDT is 0.5%, 1%, 2% and 4%, respectively, wherein the mass of PDT is 100%.
Articles and uses
The invention also provides the application of the composite material and a corresponding product.
In the present invention, the article comprises or is made from a composite material comprising or made from the composite material of the present invention.
One preferred article is a 3D printed article. The inventors have surprisingly found that the PDT of the present invention, being not only a biodegradable and biocompatible polymer, but also being liquefiable at relatively low temperatures (e.g. 130-.
Typically, the composite material or article of the present invention is applicable in the medical field, for example as a marker clip, or as a magnetic imaging material. The composite material of the present invention can be used for both medical and research purposes.
The main advantages of the invention include:
1) provides a degradable flexible biomaterial with good imaging function.
2) Provides a brand-new PDT biodegradable material/nano Fe3O4A composite material synthesis method of the material;
3) the material is innovatively applied to preparation of the postoperative bio-absorbable marker clamp for breast cancer, and the outstanding problems of poor image sensitivity, discomfort and the like caused by the traditional metal marker clamp are solved.
4) The PDT material is suitable for being made into various products by means of 3D printing and the like.
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out according to conventional conditions or according to conditions recommended by the manufacturers. Unless otherwise indicated, percentages and parts are percentages and parts by weight.
General procedure
And (3) CT measurement: respectively taking magnetic nano Fe3O4PDT/Fe at 0%, 0.5%, 1%, 2% and 4% mass concentration3O4Cutting sheet with length of 20mm, width of 4mm and thickness of 0.2mm from the composite, cutting 4 corners to form obtuse angles, and cutting different magnetic nano Fe3O4The mass concentration of the compound was placed in a CT machine and the imaging performance was observed.
And (3) measuring the mechanical property: according to the national standard GB/T1040-2006, selecting a national standard II type dumbbell-shaped sample knife, cutting sample strips for each sample by using a CP-25 type manual punching machine, and testing the sample strips by using an electronic universal tester (CMT-2503, Meitess Industrial System (China) Co., Ltd.). The gauge length was 25mm, the rate of stretching was 10mm/min, the test was carried out at 25 ℃ and a relative humidity of 50%, and the number of samples tested per group was 5. After the test is finished, obtaining values of the tensile modulus, the tensile strength and the elongation at break of the sample strip from the stress-strain image, and integrating the stress-strain image to obtain the energy at break We
The 3D printing method comprises the following steps: 3D printing was performed using a MAM dual-jet three-dimensional micro-jet free-form machine (Shanghai Fuqifan electromechanical technologies, Inc.). PDT printing conditions comprise 165 ℃ of a stock bin, 170 ℃ of a spray head, 1mm/s of XY axis movement speed and 0.1mm/s of T1 axis extrusion speed. A21-gauge needle was used, and the layer thickness was set to 0.3 mm.
Example 1 PDT preparation at different ratios
1.1. Method of producing a composite material
In this example, polymers having different mixing ratios of racemic lactide (DLLA) and trimethylene carbonate (TMC) were prepared and the performances were compared. The method comprises the following steps:
(a) taking a certain amount of monomer racemic lactide (DLLA) and trimethylene carbonate (TMC), wherein the mass ratio of the two is 100: 0,98: 2,95: 5,90: 10, 85: 15, 80: 20, 70:30 and 0: 100, respectively;
(b) selecting catalyst stannous octoate Sn (Oct)2The ratio to the total mass of the monomers was 1.25: 1000, parts by weight;
(c) vacuumizing for 4h, heating to 120 ℃ in an argon atmosphere, and reacting for 6 h;
(d) and dissolving, precipitating and purifying the product for 2-3 times by using dichloromethane and anhydrous ether, and drying in vacuum at 50 ℃ to obtain a PDT sample.
(e) The product was heat-sealed with aluminum foil and stored in a refrigerator at-20 ℃.
The results are shown in FIGS. 1-2, and show that the tensile strength and tensile modulus of the copolymer sharply decrease at a TMC ratio of more than 20%, while the elongation at break increases with an increase in the TMC ratio, and the energy at break peaks at a ratio of 70:30, so that a ratio of 70:30 is preferred as the proportion of the copolymer required to have good flexibility.
Comparative example 1
Example 1 was repeated, with the difference that the ratio of the amounts of monomeric racemic lactide (DLLA) and trimethylene carbonate (TMC), was 70:30 and in step (d) the anhydrous ether is replaced with anhydrous ethanol.
The results of elongation at break and tensile modulus are shown in fig. 3, and show that the copolymer prepared using absolute ethanol as the second solvent performed better than absolute ethyl ether, which resulted in a decrease in elongation at break from about 820% to 470% and a significant decrease in tensile modulus (from 160MPa to 35 MPa).
Example 2 PDT Material 3D printing
Example 1 was repeated, except that the ratio of the amounts of monomeric racemic lactide (DLLA) and trimethylene carbonate (TMC) was 70:30 and in step (d) the anhydrous ether is replaced with anhydrous ethanol. The article shown in fig. 4 was made after 3D printing. As can be seen from fig. 4, the PDT material has a ratio of the amounts of monomeric racemic lactide (DLLA) and trimethylene carbonate (TMC) of 70:30 has the property of easy printing and forming.
EXAMPLE 3 PDT preparation and characterization
Example 1 was repeated, except that the ratio of the amounts of monomeric racemic lactide (DLLA) and trimethylene carbonate (TMC) was 70:30 and in step (d) the anhydrous ether is replaced with anhydrous ethanol.
Results
FIG. 5 is a graph on the left side of the graph, which is a PDT sample obtained by synthesizing PDT by a lactide ring-opening polymerization method, copolymerizing monomer racemic lactide and trimethylene carbonate by using a catalyst stannous octoate under a certain condition, and performing multiple dissolution, precipitation and purification; FIG. 5 right side shows PDT sample and prepared magnetic nano Fe3O4Mixing, stirring and precipitating the particles in a dichloromethane solvent to obtain PDT/Fe3O4And (c) a complex. Drawing (A)6A is sequentially different magnetic nano Fe from left to right3O4PDT/Fe at Mass concentration3O4A composite form. FIG. 6B is PDT/Fe3O4And (4) measuring the size of the composite material.
Comparing the left and right images of FIG. 5, it is found that nano-Fe is added3O4PDT/Fe of3O4The color of the composite material is obviously deepened; comparing different magnetic nano-Fe in FIG. 6A from left to right in sequence3O4PDT/Fe at Mass concentration3O4The composite material picture shows that the composite material has better uniformity and is accompanied with magnetic nano Fe3O4The color of the composite material is deepened when the mass concentration is increased; as shown in FIG. 6B, the length of the composite was around 2 cm.
Example 4 PDT/Fe3O4Mechanical behavior of the composite
4.1 method
Mixing 5 kinds of magnetic nano Fe3O4PDT/Fe of particle mass fraction3O4The composite material (the mass fractions are respectively 0%, 0.5%, 1%, 2% and 4%) (prepared in example 1), was subjected to tensile property test according to the national standard GB/T1040-.
Table 1: PDT/Fe3O4Elastic parameter of composite material
Figure BDA0002443150690000121
4.2 results
As can be seen from Table 1, PDT copolymer is added with magnetic nano Fe3O4After the particles, the elastic modulus is obviously improved, but with the magnetic nano Fe3O4The increase in the mass percentage of the particles gradually decreases the value of the modulus of elasticity and tends to be stable. For PDT/Fe3O4The composite material (1%) was subjected to a fixed-length tensile test, and the springback condition was observed, as shown in fig. 7, and the deformation was completely recovered at 37 ℃ for 30 s.
Example 5 in vitro degradation of PDT
5.1 methods
The PDT sample film (thickness 0.2mm) prepared by the thermocompression method was cut into a square sample of 1cm × 1cm, immersed in Phosphate Buffered Saline (PBS), and placed in a 37 ℃ incubator. And taking out the bag after the bag is soaked for a set time, and observing the PDT degradation condition. And then cleaning with deionized water, drying in vacuum, and shooting the surface and section morphology.
And degrading the poly-PDT degradable material. Wherein (a) is before degradation; (b) after 4 weeks for degradation. FIG. 8 is a graph of the morphology of the material before and after degradation under electron microscope scanning, shown in FIG. 8 from both the surface and the cross section.
5.2 results
As shown in fig. 8, the appearance of the material changed relatively greatly with increasing degradation time. The material was colorless and transparent before degradation (fig. a) and turned milky white after 4 weeks of degradation (fig. b).
As can be seen from FIG. 9, the surface topography of the material changed significantly, and when the material degraded to 8 months, the surface of the material became very rough and the surface appeared granular. It can be seen from the section scanning electron microscope photo that the section of the material before degradation is relatively flat, and a plurality of relatively uniform small holes appear on the section of the material after 8 months of degradation, which indicates that the inside of the material is also relatively quickly degraded while the surface of the material is degraded.
Example 6 PDT/Fe3O4Qualitative performance under complex X-ray
6.1 methods
Respectively taking magnetic nano Fe3O4PDT/Fe at 0%, 0.5%, 1%, 2% and 4% mass concentration3O4Cutting sheet with length of 20mm, width of 4mm and thickness of 0.2mm from the composite, and cutting 4 corners to form obtuse angles by comparing different magnetic nano Fe3O4Imaging performance of mass concentration, screening magnetic nano Fe3O4The optimum mass concentration.
The result is shown in FIG. 10, which is magnetic nano Fe from left to right3O4PDT/Fe with the mass fraction of 0%, 0.5%, 1%, 2% and 4%3O4And (4) carrying out X-ray development on the compound sample. PDT/Fe3O4The visualization effect of the compound on CT scan is shown in fig. 11. Magnetic nano Fe3O4The increase in mass fraction gradually increases the composite density. Magnetic nano Fe3O4The composite with the mass fraction of 0 percent has uniform and consistent density and contains magnetic nano Fe3O4The composite is uniformly distributed with uniform high-density points along with magnetic nano Fe3O4The mass fraction is increased, and the number of high-density points is obviously increased.
6.2 results
As shown in FIG. 10, under X-ray irradiation, the complex follows the magnetic nano Fe from left to right3O4The quality fraction is increased, and the X-ray developing effect of the compound is more obvious. Illustrating PDT/Nano Fe3O4The composite material has good developability.
Example 7 PDT/Fe3O4Quantitative Performance of the Compound under CT (CT value)
7.1 methods
For PDT/Fe3O4CT test is carried out on the compound, and different nanometer Fe are recorded3O4PDT/Fe in mass fraction3O4The CT value of the complex. TABLE 2 PDT/Fe measured3O4CT values of the composite samples.
TABLE 2 PDT/Fe3O4CT value of the Complex
Mass fraction (%) Mean value (Hu) Standard deviation of Minimum value (Hu) Maximum value (Hu)
0 -378.3 113.9 -571.3 -87.8
0.5 -305.7 57.1 -519.5 -171.6
1 -177.8 75.6 -320 71.6
2 36.2 116.5 -267.7 467.6
4 177.2 308.3 -197.3 1762.2
7.2 results
As can be seen from Table 2, with Fe3O4The mass fraction increased and the CT value of the complex gradually increased. Due to the common human tissue andCT value of medium: air is-1000 Hu, fat is-90 to-70 Hu, water is 0Hu, soft tissue is 20 to 50Hu, hematoma is 6 to 80Hu, and bone is +1000 Hu. It can be known from the combination of Table 1 that in the compound with the mass fraction of 0% -1%, the nano Fe is associated with the magnetism3O4Mass increase, CT value of the complex gradually increases, but is lower than CT value of adipose tissue; in the compound with the mass fraction of 2-4%, the magnetic nano Fe is carried out3O4The mass is increased, and the CT value of the compound is gradually increased and is higher than that of fat tissue and water; but the CT value of the compound with the mass fraction of 2 percent is similar to that of soft tissue; the mass fraction of the compound of 4 percent is obviously higher than the hematoma of the tissue.
All documents referred to herein are incorporated by reference into this application as if each were individually incorporated by reference. Furthermore, it should be understood that various changes and modifications of the present invention can be made by those skilled in the art after reading the above teachings of the present invention, and these equivalents also fall within the scope of the present invention as defined by the appended claims.

Claims (10)

1. A composite material for development, said composite material being in a solid state and comprising: (a) biodegradable and biocompatible polymers; and (b) ferroferric oxide nanoparticles for development, wherein the average particle diameter of the ferroferric oxide nanoparticles is 50-500nm, and the ferroferric oxide nanoparticles are uniformly dispersed in the biodegradable and biocompatible polymer.
2. The composite material of claim 1, wherein (a) the biodegradable and biocompatible polymer is selected from the group consisting of: PDT, PGA, PLA, PCL, chitosan, hyaluronic acid, etc.
3. The composite material of claim 1, wherein said (a) biodegradable and biocompatible polymer is a PDT polymer.
4. The composite material of claim 1, wherein the average particle size of the ferroferric oxide nanoparticles for developing (b) is 50-500 nm.
5. The composite material of claim 1, wherein the ferroferric oxide nanoparticles used for developing (b) are present in an amount of 0.1 to 8 wt%, based on the total weight of the composite material.
6. The composite material of claim 1 further having the following properties:
(i) developing property: the CT value is obviously different from that of soft tissues;
(ii) biodegradability: can be degraded into micromolecular aliphatic hydroxy acid in biological environment;
(iii) biocompatibility: cytotoxicity is less than grade 1;
(iv) mechanical properties: the tensile modulus is 10-200MPa, the tensile strength is 5-20MPa, and the elongation at break is 400-900%.
7. A method of making the composite material of claim 1, comprising the steps of:
(S1) mixing the ferroferric oxide nanoparticles, the biodegradable and biocompatible polymer and the first solvent to form a first mixture, wherein the biodegradable and biocompatible polymer is soluble in the first solvent;
(S2) adding a second solvent to the first mixture, thereby forming a precipitate from the composite of the ferroferric oxide nanoparticles and the biodegradable and biocompatible polymer; and
(S3) separating the precipitate and drying to obtain the composite material of claim 1.
8. An article comprising or made from the composite material of claim 1.
9. The article of claim 8, made by the method of claim 7.
10. Use of the article according to claims 8 and 9 for the manufacture of marker clips for post-operative localization of breast cancer or also for the tracing of the degradation of polymers in vivo, as a drug carrier and for magneto-caloric therapy is provided.
CN202010270964.3A 2020-04-08 2020-04-08 Biodegradable PDT/Fe3O4Method for preparing composite material Pending CN113493600A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010270964.3A CN113493600A (en) 2020-04-08 2020-04-08 Biodegradable PDT/Fe3O4Method for preparing composite material

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010270964.3A CN113493600A (en) 2020-04-08 2020-04-08 Biodegradable PDT/Fe3O4Method for preparing composite material

Publications (1)

Publication Number Publication Date
CN113493600A true CN113493600A (en) 2021-10-12

Family

ID=77994720

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010270964.3A Pending CN113493600A (en) 2020-04-08 2020-04-08 Biodegradable PDT/Fe3O4Method for preparing composite material

Country Status (1)

Country Link
CN (1) CN113493600A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115216065A (en) * 2022-06-21 2022-10-21 王旭 Composite rubber ring containing silver powder and magnetic powder, preparation method thereof and application of composite rubber ring as new auxiliary chemotherapy positioning mark

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115216065A (en) * 2022-06-21 2022-10-21 王旭 Composite rubber ring containing silver powder and magnetic powder, preparation method thereof and application of composite rubber ring as new auxiliary chemotherapy positioning mark

Similar Documents

Publication Publication Date Title
Liu et al. Covalent crosslinking of graphene oxide and carbon nanotube into hydrogels enhances nerve cell responses
Torabinejad et al. Synthesis and characterization of nanocomposite scaffolds based on triblock copolymer of L-lactide, ε-caprolactone and nano-hydroxyapatite for bone tissue engineering
Selvakumar et al. Synthesis and characterization of novel polycarbonate based polyurethane/polymer wrapped hydroxyapatite nanocomposites: mechanical properties, osteoconductivity and biocompatibility
US20060069168A1 (en) Vascular embolization material
CN104744661A (en) Hydrophilic degradable segmented polyurethane as well as preparation method and application thereof
JP2000516978A (en) Hyaluronic acid esters, yarns and biocompatible materials containing the same and their use in surgery
JP5217149B2 (en) Biodegradable spherical particles
US20070117959A1 (en) Novel polyesters
Duarah et al. Smart self-tightening surgical suture from a tough bio-based hyperbranched polyurethane/reduced carbon dot nanocomposite
CA2626881C (en) Biodegradable particle and production method thereof
CN113493600A (en) Biodegradable PDT/Fe3O4Method for preparing composite material
JP5398112B2 (en) Biodegradable particles and method for producing the same
Ding et al. Polymerization-induced self-assembly of large-scale iohexol nanoparticles as contrast agents for X-ray computed tomography imaging
JP5223182B2 (en) Biodegradable particles and method for producing the same
Bhowmick et al. Novel magnetic antimicrobial nanocomposites for bone tissue engineering applications
Chen et al. Biodegradable polyphosphazenes for regenerative engineering
Abdalkarim et al. Supermagnetic cellulose nanocrystal hybrids reinforced PHBV nanocomposites with high sensitivity to intelligently detect water vapor
Pryadko A et al. Electrospun magnetic composite poly-3-hydroxybutyrate/magnetite scaffolds for biomedical applications: Composition, structure, magnetic properties, and biological performance
Guo et al. Preparation of doxorubicin loaded Poly (ethylene glycol)-Poly (ε-caprolactone)-hydroxyapatite fibres as drug delivery systems
Cortés-Ortiz et al. Plasma functionalized scaffolds of polyhydroxybutyrate electrospun fibers for pancreatic beta cell cultures
Dodda et al. Bioresorbable films of polycaprolactone blended with poly (lactic acid) or poly (lactic-co-glycolic acid)
US10507051B2 (en) X-ray detectable bioabsorbable bone screw
CN109641084A (en) It is anti-sticking that composition is used in conjunction
US9737621B2 (en) MRI-visible hydrophobic copolymer
Xia et al. A potential dual-modality optical imaging probe based on the pH-responsive micelle

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination